T
2.33
0.09 (4.02%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | TuHURA Biosciences, Inc. | 看涨 | 看跌 |
AIStockmoo 评分
0.4
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 1.0 |
| 技术振荡指标 | 0.5 |
| 平均 | 0.38 |
|
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 41.96% |
| 机构持股比例 | 8.43% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Suncoast Equity Management | 31 Dec 2025 | 104,409 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合